Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (EGX: RMDA)

Market Cap	5.50B
Revenue (ttm)	2.10B
Net Income (ttm)	226.67M
Shares Out	1.50B
EPS (ttm)	0.15
PE Ratio	24.15
Forward PE	12.08
Dividend	0.07 (2.09%)
Ex-Dividend Date	Jun 25, 2024

Volume	64,594,760
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1.480 - 3.710
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About RMDA

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt. It manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use; and diagnostic reagents for individuals, laboratories, and hospitals. The company offers a portfolio of products in various therapeutic areas, such as anti-infective, anti-diabetic, respiratory, ophthalmology, gastrointestinal tract, cardiov...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Country: Egypt
• Stock Exchange: Egyptian Stock Exchange
• Ticker Symbol: RMDA

Financial Performance

In 2023, RMDA's revenue was 1.92 billion, an increase of 29.54% compared to the previous year's 1.48 billion. Earnings were 223.50 million, a decrease of -2.37%.